anti-amyloid-therapies

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 53/100

   A Cross-Sectional Survey of Knowledge, Confidence, and Decision-Making in Acute Stroke in the Era of Anti-Amyloid Therapies

   ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of the American College of Clinical Pharmacy : JACCP · 2026-10-01 · Treatments

   EM providers and pharmacists demonstrated substantial gaps in preparedness for patients receiving AATs, including limited knowledge, low confidence, minimal clinical experience, and inadequate institutional support.

   • Treatments
2. 50/100

   Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup

   ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026-04-01 · Treatments

   In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials.

   • Treatments
   • Side Effects
   • Brain Scans
3. 50/100

   White matter hyperintensities in Alzheimer's disease in the era of anti-amyloid therapies

   ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) · 2026-04-01 · Treatments

   White matter hyperintensities (WMHs) are highly prevalent in Alzheimer's disease (AD) and arise from interacting vascular pathologies (including hypertensive small vessel disease and cerebral amyloid angiopathy) alongside inflammatory and neurodegenerative processes.

   • Treatments
   • Brain Scans
   • Side Effects
4. 47/100

   A regional framework for the detection and management of ARIA with anti-amyloid therapies in early Alzheimer's disease in Asia

   ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease · 2026-01-17 · Treatments

   Alzheimer's disease (AD) is a growing public health concern in Asia, with an increasing prevalence driven by demographic shifts and rising life expectancy.

   • Treatments
   • Side Effects
5. 43/100

   Anti-Amyloid Therapies for Early Alzheimer's Disease: Evidence-Based Recommendations

   ✓ Peer-reviewed alzhub usefulness score 43 out of 100. South Dakota medicine : the journal of the South Dakota State Medical Association · 2026-01-01 · Treatments

   Anti-amyloid therapies offer a meaningful step forward in AD management, but their use requires careful patient selection, biomarker confirmation, and adherence to safety protocols.

   • Treatments
   • Side Effects
6. 45/100

   Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti-amyloid therapies

   ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023-12-12 · Treatments

   New mouse models of AD pathologies will add to the research armamentarium, but the early models have accurately predicted responses to amyloid therapies in humans.

   • Treatments
   • Brain Biology

All topic tags with their study counts